Meeting
2018 ASCO Annual Meeting
KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma.
Authors
Birgit Geoerger
Gustave Roussy, Villejuif, France
Birgit Geoerger , Hyoung Jin Kang , Michal Yalon-Oren , Lynley V. Marshall , Catherine Vezina , Alberto S. Pappo , Theodore Willis Laetsch , Antonio Sergio Petrilli , Martin Ebinger , Jacek Toporski , Julia Glade-Bender , Wayne Nicholls , Elizabeth Fox , Steven G. DuBois , Margaret Macy , Susan Lerner Cohn , Kumudu Pathiraja , Scott J. Diede , Scot Ebbinghaus , Navin R. Pinto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02332668
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10525)
DOI
10.1200/JCO.2018.36.15_suppl.10525
Abstract #
10525
Poster Bd #
198
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1+ advanced, relapsed, or refractory solid tumor or lymphoma.
First Author: Birgit Geoerger
Poster
2022 ASCO Annual Meeting
Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).
First Author: Diwakar Davar
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Annual Meeting
First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.
First Author: Adil Daud